Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2023

Open Access 01-12-2023 | Review

Payload diversification: a key step in the development of antibody–drug conjugates

Authors: Louise Conilh, Lenka Sadilkova, Warren Viricel, Charles Dumontet

Published in: Journal of Hematology & Oncology | Issue 1/2023

Login to get access

Abstract

Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that currently combines the selectivity of monoclonal antibodies with the potency of a payload consisting of cytotoxic agents. For many years microtubule targeting and DNA-intercalating agents were at the forefront of ADC development. The recent approval and clinical success of trastuzumab deruxtecan (Enhertu®) and sacituzumab govitecan (Trodelvy®), two topoisomerase 1 inhibitor-based ADCs, has shown the potential of conjugating unconventional payloads with differentiated mechanisms of action. Among future developments in the ADC field, payload diversification is expected to play a key role as illustrated by a growing number of preclinical and clinical stage unconventional payload-conjugated ADCs. This review presents a comprehensive overview of validated, forgotten and newly developed payloads with different mechanisms of action.
Literature
1.
Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8:473–80.CrossRef
2.
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315–37.CrossRef
3.
Bross PF, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490–6.
4.
Petersdorf SH, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854–60.CrossRef
5.
Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327–44.CrossRef
6.
do Pazo C, Nawaz K, Webster RM. The oncology market for antibody–drug conjugates. Nat Rev Drug Discov. 2021;20:583–4.CrossRef
7.
Arlotta KJ, Owen SC. Antibody and antibody derivatives as cancer therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11: e1556.CrossRef
8.
Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-engineering for modulated effector functions—improving antibodies for cancer treatment. Antibodies. 2020;9(4):64.CrossRef
9.
Qiao J, Al-Tamimi M, Baker RI, Andrews RK, Gardiner EE. The platelet Fc receptor. FcγRIIa Immunol Rev. 2015;268:241–52.CrossRef
10.
Uppal H, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2015;21:123–33.CrossRef
11.
Pegram MD, et al. First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol Cancer Ther. 2021;20:1442–53.CrossRef
12.
Deonarain MP. Miniaturised ’antibody’-drug conjugates for solid tumours? Drug Discov Today Technol. 2018;30:47–53.CrossRef
13.
Deonarain MP, Yahioglu G. Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy. Expert Opin Drug Discov. 2021;16:613–24.CrossRef
14.
Deonarain MP, et al. Small-format drug conjugates: a viable alternative to ADCs for solid tumours? Antibodies. 2018;7(2):16.CrossRef
15.
Rypáček F, Drobník J, Chmelař V, Kálal J. The renal excretion and retention of macromolecules. Pflugers Arch. 1982;392:211–7.CrossRef
16.
Pyzik M, et al. The neonatal Fc receptor (FcRn): a misnomer? Front Immunol. 2019;10:1540.CrossRef
17.
Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit.’ Nat Rev Drug Discov. 2018;17:197–223.CrossRef
18.
Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33–46.CrossRef
19.
Herrera AF, et al. Anti-CD79B antibody-drug conjugate DCDS0780A in patients with B-cell non-hodgkin lymphoma: phase 1 dose-escalation study. Clin Cancer Res. 2022;28:1294–301.CrossRef
20.
Zhou Q. Site-specific antibody conjugation for ADC and beyond. Biomedicines. 2017;5:E64.CrossRef
21.
Duivelshof BL, et al. Glycan-mediated technology for obtaining homogeneous site-specific conjugated antibody-drug conjugates: synthesis and analytical characterization by using complementary middle-up LC/HRMS analysis. Anal Chem. 2020;92:8170–7.CrossRef
22.
Zhang L, et al. A simple and efficient method to generate dual site-specific conjugation ADCs with cysteine residue and an unnatural amino acid. Bioconjugate Chem. 2021;32:1094–104.CrossRef
23.
Hussain AF, et al. Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches. Pharmaceuticals. 2021;14(4):343.CrossRef
24.
Dai Z, et al. Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases. Sci Adv. 2020;6(23):eaba6752.CrossRef
25.
Puthenveetil S, et al. Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate. PLoS ONE. 2017;12: e0178452.CrossRef
26.
Buecheler JW, Winzer M, Tonillo J, Weber C, Gieseler H. Impact of payload hydrophobicity on the stability of antibody-drug conjugates. Mol Pharm. 2018;15:2656–64.CrossRef
27.
Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014;11:99–109.CrossRef
28.
Lyon RP, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33:733–5.CrossRef
29.
Hamblett KJ, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70.CrossRef
30.
Simmons JK, Burke PJ, Cochran JH, Pittman PG, Lyon RP. Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation. Toxicol Appl Pharmacol. 2020;392: 114932.CrossRef
31.
Li Q, et al. PEG linker improves antitumor efficacy and safety of affibody-based drug conjugates. Int J Mol Sci. 2021;22:1540.CrossRef
32.
Shao S, et al. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG. Bioorg Med Chem Lett. 2018;28:1363–70.CrossRef
33.
Burke PJ, et al. Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates. Mol Cancer Ther. 2017;16:116–23.CrossRef
34.
Sonzini S, et al. Improved physical stability of an antibody-drug conjugate using host-guest chemistry. Bioconjug Chem. 2020;31:123–9.CrossRef
35.
Viricel W, et al. Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. Chem Sci. 2019;10:4048–53.CrossRef
36.
Conilh L, et al. Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform. Pharmaceuticals. 2021;14(3):247.CrossRef
37.
Dovgan I, et al. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency. Sci Rep. 2020;10:7691.CrossRef
38.
Yurkovetskiy AV, et al. A polymer-based antibody-Vinca drug conjugate platform: characterization and preclinical efficacy. Cancer Res. 2015;75:3365–72.CrossRef
39.
Okajima D, et al. Datopotamab Deruxtecan, a novel TROP2-directed antibody–drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329–40.CrossRef
40.
Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17:6389–97.CrossRef
41.
42.
Widdison WC, Chari RVJ. Factors involved in the design of cytotoxic payloads for antibody–drug conjugates. In: Phillips GL editor Antibody-drug conjugates and immunotoxins: from pre-clinical development to therapeutic applications. Springer; 2013. pp. 93–115. https://​doi.​org/​10.​1007/​978-1-4614-5456-4_​6.
43.
Mantaj J, Jackson PJM, Rahman KM, Thurston DE. From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs). Angew Chem Int Ed Engl. 2017;56:462–88.CrossRef
44.
Yaghoubi S, et al. Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. J Cell Physiol. 2020;235:31–64.CrossRef
45.
Saber H, Simpson N, Ricks TK, Leighton JK. An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates. Regul Toxicol Pharmacol. 2019;107: 104429.CrossRef
46.
Hartley JA. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther. 2021;21:931–43.CrossRef
47.
48.
49.
50.
Criscitiello C, Morganti S, Curigliano G. Antibody–drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14:20.CrossRef
51.
Moek KL, de Groot DJA, de Vries EGE, Fehrmann RSN. The antibody-drug conjugate target landscape across a broad range of tumour types. Ann Oncol. 2017;28:3083–91.CrossRef
52.
Ogitani Y, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097–108.CrossRef
53.
Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496–512.CrossRef
54.
Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6:789–802.CrossRef
55.
Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421–33.CrossRef
56.
Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 2013;8:82–95.CrossRef
57.
Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 1994;86:836–42.CrossRef
58.
Zunino F, Pratesi G. Camptothecins in clinical development. Expert Opin Investig Drugs. 2004;13:269–84.CrossRef
59.
Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148: 104398.CrossRef
60.
Thomas A, Pommier Y. Targeting topoisomerase I in the era of precision medicine. Clin Cancer Res. 2019;25:6581–9.CrossRef
61.
Takegawa N, et al. DS-8201a, a new HER2-targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141:1682–9.CrossRef
62.
Abou-Alfa GK, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293–300.CrossRef
63.
Ogitani Y, et al. Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. Bioorg Med Chem Lett. 2016;26:5069–72.CrossRef
64.
Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039–46.CrossRef
65.
Takegawa N, et al. DS-8201a, a new HER2-targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141:1682–9.CrossRef
66.
Iwata TN, et al. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17:1494–503.CrossRef
67.
Nagai Y, Oitate M, Shiozawa H, Ando O. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys. Xenobiotica. 2019;49:1086–96.CrossRef
68.
Modi S, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–21.CrossRef
69.
Shitara K, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30.CrossRef
70.
Research, C. for D. E. and. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer. FDA. 2022.
71.
Cortés J, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143–54.CrossRef
72.
Li BT, et al. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer. N Engl J Med. 2022;386:241–51.CrossRef
73.
Siena S, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22:779–89.CrossRef
74.
75.
Liu H, et al. Abstract P196: novel hydrophilic drug linkers enable exatecan-based antibody-drug conjugates with promising physiochemical properties and in vivo activity. Mol Cancer Ther. 2021;20:P196.CrossRef
76.
77.
78.
79.
Li W, et al. Synthesis and evaluation of camptothecin antibody-drug conjugates. ACS Med Chem Lett. 2019;10:1386–92.CrossRef
80.
81.
Gupta E, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723–5.
82.
Haaz MC, Rivory L, Riché C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 1998;58:468–72.
83.
84.
Moon S-J, et al. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008;51:6916–26.CrossRef
85.
Govindan SV, Cardillo TM, Moon S-J, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009;15:6052–61.CrossRef
86.
Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015;12:1836–47.CrossRef
87.
Cardillo TM, et al. IMMU-140, a novel SN-38 antibody-drug conjugate targeting HLA-DR, mediates dual cytotoxic effects in hematologic cancers and malignant melanoma. Mol Cancer Ther. 2018;17:150–60.CrossRef
88.
Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012;11:224–34.CrossRef
89.
Govindan SV, et al. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther. 2013;12:968–78.CrossRef
90.
Yao Y, et al. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates. J Control Release. 2015;220:5–17.CrossRef
91.
Yasunaga M, Manabe S, Tarin D, Matsumura Y. Tailored immunoconjugate therapy depending on a quantity of tumor stroma. Cancer Sci. 2013;104:231–7.CrossRef
92.
Yasunaga M, Manabe S, Tarin D, Matsumura Y. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjugate Chem. 2011;22:1776–83.CrossRef
93.
Yasunaga M, Manabe S, Matsumura Y. Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. Sci Rep. 2017;7:10735.CrossRef
94.
Burke PJ, et al. Design, synthesis, and biological evaluation of antibody−drug conjugates comprised of potent camptothecin analogues. Bioconjugate Chem. 2009;20:1242–50.CrossRef
95.
Gupta N, et al. Development of a facile antibody–drug conjugate platform for increased stability and homogeneity. Chem Sci. 2017;8:2387–95.CrossRef
96.
Lyski RD, et al. Development of novel antibody-camptothecin conjugates. Mol Cancer Ther. 2021;20:329–39.CrossRef
97.
Ryan M, et al. SGN-CD30C, an investigational CD30-Directed camptothecin antibody-drug conjugate (ADC), Shows strong anti tumor activity and superior tolerability in preclinical studies. Blood. 2020;136:41–2.CrossRef
98.
Lyski R, et al. Abstract 2885: discovery of a tripeptide-based camptothecin drug-linker for antibody-drug conjugates with potent antitumor activity and a broad therapeutic window. Can Res. 2020;80:2885.CrossRef
99.
Kummar S, et al. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78:73–81.CrossRef
100.
Lv P-C, et al. Design, synthesis, and biological evaluation of potential prodrugs related to the experimental anticancer agent indotecan (LMP400). J Med Chem. 2016;59:4890–9.CrossRef
101.
Kurtzberg LS, et al. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res. 2011;17:2777–87.CrossRef
102.
Sooryakumar D, Dexheimer TS, Teicher BA, Pommier Y. Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. Mol Cancer Ther. 2011;10:1490–9.CrossRef
103.
Marzi L, et al. Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors. Mol Cancer Ther. 2018;17:1694–704.CrossRef
104.
105.
Elias DJ, et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma1. Can Res. 1990;50:4154–9.
106.
Saleh MN, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol. 2000;18:2282–92.CrossRef
107.
Tolcher AW, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17:478–84.CrossRef
108.
Sapra P, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res. 2005;11:5257–64.CrossRef
109.
Luong A, Issarapanichkit T, Kong SD, Fong R, Yang J. pH-Sensitive, N-ethoxybenzylimidazole (NEBI) bifunctional crosslinkers enable triggered release of therapeutics from drug delivery carriers. Org Biomol Chem. 2010;8:5105–9.CrossRef
110.
Stefan N, et al. Highly potent, anthracycline-based antibody-drug conjugates generated by enzymatic, Site-specific Conjugation. Mol Cancer Ther. 2017;16:879–92.CrossRef
111.
Junttila MR, et al. Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer. Sci Transl Med. 2015;7(314):314ra186.CrossRef
112.
113.
Sadilkova LK, et al. Abstract 1204: SO-N102, a novel CLDN182-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels. Cancer Res. 2021;81:1204.CrossRef
114.
Yu S-F, et al. A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clin Cancer Res. 2015;21:3298–306.CrossRef
115.
D’Amico L, et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer. 2019;7:16.CrossRef
116.
Dal Corso A, Gébleux R, Murer P, Soltermann A, Neri D. A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo. J Control Release. 2017;264:211–8.CrossRef
117.
Holte D, et al. Evaluation of PNU-159682 antibody drug conjugates (ADCs). Bioorg Med Chem Lett. 2020;30: 127640.CrossRef
118.
119.
Nilchan N, et al. Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation. Antib Ther. 2019;2:71–8.
120.
Kato Y, et al. A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate. J Med Chem. 1984;27:1602–7.CrossRef
121.
122.
Pietersz GA, Smyth MJ, McKenzie IF. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. Cancer Res. 1988;48:926–31.
123.
Rowland AJ, Pietersz GA, McKenzie IF. Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates. Cancer Immunol Immunother. 1993;37:195–202.CrossRef
124.
Ghanemi M, et al. Specific targeting of HER2-positive head and neck squamous cell carcinoma line HN5 by idarubicin-ZHER2 affibody conjugate. Curr Cancer Drug Targets. 2019;19:65–73.CrossRef
125.
Laham-Karam N, Pinto GP, Poso A, Kokkonen P. Transcription and translation inhibitors in cancer treatment. Front Chem. 2020;8:276.CrossRef
126.
Lindell TJ, Weinberg F, Morris PW, Roeder RG, Rutter WJ. Specific inhibition of nuclear RNA polymerase II by α-amanitin. Science. 1970;170:447–9.CrossRef
127.
Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006;91:140–9.CrossRef
128.
Garcia J, et al. Amanita phalloides poisoning: mechanisms of toxicity and treatment. Food Chem Toxicol. 2015;86:41–55.CrossRef
129.
Pahl A, Lutz C, Hechler T. Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov Today Technol. 2018;30:85–9.CrossRef
130.
Barbanti-Brodano G, Fiume L. Selective killing of macrophages by amanitin-albumin conjugates. Nat New Biol. 1973;243:281–3.CrossRef
131.
Danielczyk A, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother. 2006;55:1337–47.CrossRef
132.
Hechler T, Kulke M, Mueller C, Pahl A, Anderl J. Abstract 664: amanitin-based antibody-drug conjugates targeting the prostate-specific membrane antigen. Can Res. 2014;74:664.CrossRef
133.
Gallo F, et al. Enhancing the pharmacokinetics and antitumor activity of an α-amanitin-based small-molecule drug conjugate via conjugation with an Fc domain. J Med Chem. 2021;64:4117–29.CrossRef
134.
Davis MT, Preston JF. A conjugate of alpha-amanitin and monoclonal immunoglobulin G to Thy 1.2 antigen is selectively toxic to T lymphoma cells. Science. 1981;213:1385–8.CrossRef
135.
Figueroa-Vazquez V, et al. HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther. 2021;20:367–78.CrossRef
136.
137.
Moldenhauer G, et al. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst. 2012;104:622–34.CrossRef
138.
Kulke M, et al. Abstract 735: SAR of amanitin and optimization of linker-amanitin derivatives for solid tumors. Can Res. 2018;78:735.CrossRef
139.
Świderska KW, Szlachcic A, Opaliński Ł, Zakrzewska M, Otlewski J. FGF2 dual warhead conjugate with monomethyl auristatin E and α-amanitin displays a cytotoxic effect towards cancer cells overproducing FGF receptor 1. Int J Mol Sci. 2018;19:2098.CrossRef
140.
Barbanti-Brodano G, Derenzini M, Fiume L. Toxic action of a phalloidin-albumin conjugate on cells with a high protein uptake. Nature. 1974;248:63–5.CrossRef
141.
Hinman, L. M. & Yarranton, G. Chapter 25. New approaches to non-immunogenic monoclonal antibody cancer therapies. In: Bristol JA editor Annual Reports in Medicinal Chemistry, 1993. vol. 28, pp. 237–246.
142.
Nielsen C, Casteel M, Didier A, Dietrich R, Märtlbauer E. Trichothecene-induced cytotoxicity on human cell lines. Mycotoxin Res. 2009;25:77–84.CrossRef
143.
Liu X, Bushnell DA, Kornberg RD. RNA polymerase II transcription: structure and mechanism. Biochim Biophys Acta. 2013;1829:2–8.CrossRef
144.
Noel P, et al. Triptolide and its derivatives as cancer therapies. Trends Pharmacol Sci. 2019;40:327–41.CrossRef
145.
Hayashi M, et al. Novel antibody-drug conjugate with anti-CD26 humanized monoclonal antibody and transcription factor IIH (TFIIH) inhibitor, triptolide, inhibits tumor growth via impairing mRNA synthesis. Cancers. 2019;11:E1138.CrossRef
146.
Zhang K, et al. Cetuximab-triptolide conjugate suppresses the growth of EGFR-overexpressing lung cancers through targeting RNA polymerase II. Mol Ther Oncolytics. 2020;18:304–16.CrossRef
147.
Wei D, et al. Site-specific construction of triptolide-based antibody-drug conjugates. Bioorg Med Chem. 2021;51: 116497.CrossRef
148.
149.
McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018;138:183–211.CrossRef
150.
Cini E, et al. Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation †Electronic supplementary information (ESI) available: experimental procedures, biological activity data, NMR spectra for characterisation. Chem Sci. 2018;9:6490–6. https://​doi.​org/​10.​1039/​c7sc05266a.CrossRef
151.
Milazzo FM, et al. ErbB2 targeted epigenetic modulation: anti-tumor efficacy of the ADC trastuzumab-HDACi ST8176AA1. Front Oncol. 2020;9:1534.CrossRef
152.
Cianferotti C, et al. Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition. Chem Commun. 2021;57:867–70.CrossRef
153.
Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65–80.CrossRef
154.
Tse C, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–8.CrossRef
155.
Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.CrossRef
156.
Trudel S, et al. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood. 2007;109:5430–8.CrossRef
157.
Baggstrom MQ, et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6:1757–60.CrossRef
158.
Hu Y, et al. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer Lett. 2018;423:47–59.CrossRef
159.
Lessene G, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 2013;9:390–7.CrossRef
160.
Zhang H, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14:943–51.CrossRef
161.
162.
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res. 2020;152: 104609.CrossRef
163.
Jaiswal N, Akhtar J, Singh SP, Badruddeen, Ahsan F. An overview on genistein and its various formulations. Drug Res. 2019;69:305–13.CrossRef
164.
Messinger Y, et al. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates. Clin Cancer Res. 1998;4:165–70.
165.
Ek O, et al. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate. Leuk Lymphoma. 1998;30:389–94.CrossRef
166.
Chen C-L, et al. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies. J Clin Pharmacol. 1999;39:1248–55.CrossRef
167.
Uckun FM, et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res. 1999;5:3906–13.
168.
Uckun FM, et al. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. Clin Cancer Res. 1998;4:1125–34.
169.
Gentile MS, et al. Targeting colon cancer cells with genistein-17.1A immunoconjugate. Int J Oncol. 2003;22:955–9.
170.
Zhou D, et al. Novel PIKK inhibitor antibody-drug conjugates: synthesis and anti-tumor activity. Bioorg Med Chem Lett. 2019;29:943–7.CrossRef
171.
Wang RE, et al. An immunosuppressive antibody-drug conjugate. J Am Chem Soc. 2015;137:3229–32.CrossRef
172.
Chao W-T, et al. Abstract 3729: developing cetuximab-staurosporine conjugate as the therapeutic medicine in KRAS/BRAF mutated colon cancer cells. Can Res. 2018;78:3729.CrossRef
173.
Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING Agonists as Cancer Therapeutics. Cancers. 2021;13:2695.CrossRef
174.
175.
176.
Ackerman SE, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2:18–33.CrossRef
177.
Ackerman SE, et al. Abstract 1559: TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models. Can Res. 2019;79:1559.CrossRef
178.
179.
180.
181.
182.
Metz H, et al. SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. JCO. 2020;38:3110–3110.CrossRef
183.
Comeau MR, et al. Abstract 4537: SBT6050, a HER2-directed TLR8 ImmunoTACTMtherapeutic, is a potent human myeloid cell agonist that provides opportunity for single agent clinical activity. Can Res. 2020;80:4537.CrossRef
184.
Gadd AJR, Greco F, Cobb AJA, Edwards AD. Targeted activation of toll-like receptors: conjugation of a toll-like receptor 7 agonist to a monoclonal antibody maintains antigen binding and specificity. Bioconjugate Chem. 2015;26:1743–52.CrossRef
185.
Ackerman SE, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2:18–33.CrossRef
186.
He L, et al. Immune modulating antibody-drug conjugate (IM-ADC) for cancer immunotherapy. J Med Chem. 2021;64:15716–26.CrossRef
187.
188.
189.
Banerjee M, et al. Abstract LB-061: CRD5500: a versatile small molecule STING agonist amenable to bioconjugation as an ADC. Cancer Research. 2019;79:LB-061.CrossRef
190.
191.
Duvall JR, et al. Abstract 1738: XMT-2056, a well-tolerated, immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity. Can Res. 2021;81:1738.CrossRef
192.
193.
Scott AM, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res. 2005;11:4810–7.CrossRef
194.
Park H-K, et al. Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1. Exp Mol Med. 2020;52:79–91.CrossRef
195.
Mandler R, Dadachova E, Brechbiel JK, Waldmann TA, Brechbiel MW. Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate. Bioorg Med Chem Lett. 2000;10:1025–8.CrossRef
196.
Mandler R, Kobayashi H, Davis MY, Waldmann TA, Brechbiel MW. Modifications in synthesis strategy improve the yield and efficacy of geldanamycin−herceptin immunoconjugates. Bioconjugate Chem. 2002;13:786–91.CrossRef
197.
Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA. Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res. 2004;64:1460–7.CrossRef
198.
Burke PJ, et al. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system. Bioorg Med Chem Lett. 2009;19:2650–3.CrossRef
199.
Lim KS, Lee DY, Han S, Bull DA, Won Y-W. Targeted delivery of heat shock protein 90 inhibitors prevents growth of HER2-positive tumor. Biomaterials. 2021;273: 120817.CrossRef
200.
Effenberger KA, Urabe VK, Jurica MS. Modulating splicing with small molecular inhibitors of the spliceosome. Wiley Interdiscip Rev RNA. 2017;8(2):e1381.CrossRef
201.
Lee SC-W, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016;22:976–86.CrossRef
202.
Puthenveetil S, et al. Natural product splicing inhibitors: a new class of antibody-drug conjugate (ADC) payloads. Bioconjug Chem. 2016;27:1880–8.CrossRef
203.
Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014;20:1735–40.CrossRef
204.
Jeffrey SC, De Brabander J, Miyamoto J, Senter PD. Expanded utility of the β-glucuronide linker: ADCs that deliver phenolic cytotoxic agents. ACS Med Chem Lett. 2010;1:277–80.CrossRef
205.
Almaliti J, et al. Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents. Eur J Med Chem. 2019;161:416–32.CrossRef
206.
Stanton BZ, Chory EJ, Crabtree GR. Chemically induced proximity in biology and medicine. Science. 2018;359:eaao5902.CrossRef
207.
208.
209.
Pillow TH, et al. Antibody Conjugation of a chimeric BET degrader enables in vivo activity. ChemMedChem. 2020;15:17–25.CrossRef
210.
Dragovich PS, et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 1: exploration of antibody linker, payload loading, and payload molecular properties. J Med Chem. 2021;64:2534–75.CrossRef
211.
Dragovich PS, et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: improvement of in vitro antiproliferation activity and in vivo antitumor efficacy. J Med Chem. 2021;64:2576–607.CrossRef
212.
Maneiro M, et al. Antibody–PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4. ACS Chem Biol. 2020;15:1306–12.CrossRef
213.
Chuang SH et al. Conjugués Anticorps-Protac. 2019
214.
Dragovich PS, et al. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα). Bioorg Med Chem Lett. 2020;30: 126907.CrossRef
215.
216.
Neumann CS, et al. Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates. Mol Cancer Ther. 2018;17:2633–42.CrossRef
217.
Karpov AS, et al. Nicotinamide phosphoribosyltransferase inhibitor as a novel payload for antibody-drug conjugates. ACS Med Chem Lett. 2018;9:838–42.CrossRef
218.
El-Nassan HB. Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. Eur J Med Chem. 2013;62:614–31.CrossRef
219.
Lerchen H-G, et al. Antibody-drug conjugates with pyrrole-based KSP inhibitors as the payload class. Angew Chem Int Ed Engl. 2018;57:15243–7.CrossRef
220.
Lerchen H-G, et al. Tailored linker chemistries for the efficient and selective activation of ADCs with KSPi payloads. Bioconjugate Chem. 2020;31:1893–8.CrossRef
221.
Karpov AS, et al. Discovery of potent and selective antibody-drug conjugates with Eg5 inhibitors through linker and payload optimization. ACS Med Chem Lett. 2019;10:1674–9.CrossRef
222.
Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14:20.CrossRef
223.
Su Z, et al. Antibody–drug conjugates: recent advances in linker chemistry. Acta Pharmaceutica Sinica B. 2021;11:3889–907.CrossRef
224.
225.
Xiao D, et al. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate. Theranostics. 2021;11:2550–63.CrossRef
226.
Joubert N, Denevault-Sabourin C, Bryden F, Viaud-Massuard M-C. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy. Eur J Med Chem. 2017;142:393–415.CrossRef
227.
Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736–42.CrossRef
228.
Szot C, et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest. 2018;128:2927–43.CrossRef
229.
Love EA, et al. Developing an antibody-drug conjugate approach to selective inhibition of an extracellular protein. ChemBioChem. 2019;20:754–8.CrossRef
230.
231.
Theocharopoulos C, Lialios P-P, Samarkos M, Gogas H, Ziogas DC. Antibody-drug conjugates: functional principles and applications in oncology and beyond. Vaccines. 2021;9:1111.CrossRef
232.
Dragovich PS. Antibody-drug conjugates for immunology. J Med Chem. 2022;65:4496–9.CrossRef
233.
Hobson AD, et al. Design and development of glucocorticoid receptor modulators as immunology antibody-drug conjugate payloads. J Med Chem. 2022;65:4500–33.CrossRef
234.
Dragovich PS. Antibody-drug conjugates for immunology. J Med Chem. 2022;65:4496–9.CrossRef
235.
Lehar SM, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015;527:323–8.CrossRef
236.
Lim RKV, et al. Targeted delivery of LXR agonist using a site-specific antibody-drug conjugate. Bioconjug Chem. 2015;26:2216–22.CrossRef
237.
Trudel S, et al. Targeting B-Cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma: a dose-escalation and expansion phase 1 trial (BMA117159). Lancet Oncol. 2018;19:1641–53.CrossRef
238.
Lonial S, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–21.CrossRef
239.
Swain SM, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106: 102378.CrossRef
Metadata
Title
Payload diversification: a key step in the development of antibody–drug conjugates
Authors
Louise Conilh
Lenka Sadilkova
Warren Viricel
Charles Dumontet
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2023
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01397-y

Other articles of this Issue 1/2023

Journal of Hematology & Oncology 1/2023 Go to the issue

Review

Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications

Review

Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients

Correction

Correction: SELP Asp603Asn and severe thrombosis in COVID-19 males

Review

Exploiting RIG-I-like receptor pathway for cancer immunotherapy

Review

The Notch signaling pathway: a potential target for cancer immunotherapy

Editorial

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits